Top Markets
#1 Black Phoenix Black Phoenix +21,376.82%
#2 Nesa Nesa +750.04%
#3 ADO Protocol ADO Protocol +101.88%
#4 Cortex Cortex +93.70%
#5 Ontology Gas Ontology Gas +69.25%
#6 Kinesis Silver Kinesis Silver +54.02%
#7 OpenEden OpenEden +26.38%
#8 Magma Finance Magma Finance +24.43%
#9 PondCoin PondCoin +24.08%
#10 QuantixAI QuantixAI +23.16%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Simcere Pharmaceutical Group Limited Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group Limited

2096
Rang in Aktien #4368
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Aktienkurs
$1.48
Marktkapitalisierung
$3.81B
Veränderung (1 Tag)
0.61%
Veränderung (1 Jahr)
-19.90%
Land
CN
Handel Simcere Pharmaceutical Group Limited (2096)

Kategorie

Healthcare
Gewinn für Simcere Pharmaceutical Group Limited (2096)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Simcere Pharmaceutical Group Limited betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Simcere Pharmaceutical Group Limited von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH